nach oben

18.05.2024 | Acute Pain Medicine (R Urman, Section Editor)

Emerging Medications and Strategies in Acute Pain Management: Evolving Role of Novel Sodium and Calcium Channel Blockers, Peptide-Based Pharmacologic Drugs, and Non-Medicinal Methods

verfasst von: Alan D. Kaye, Driskell R. Greene, Catherine Nguyen, Amanda Ragland, Mason P. Granger, William Peyton Wilhite, Kylie Dufrene, Sahar Shekoohi, Christopher L. Robinson

Erschienen in: Current Pain and Headache Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The present investigation evaluated integration of novel medication technology to enhance treatment options, while improving patient outcomes in acute pain management. In this regard, we focused on determining the role of development and utilization of cutting-edge pharmaceutical advancements, such as targeted drug delivery systems, as well as non-pharmacologic interventions in addressing acute pain states. Further research in this area is warranted related to the need for increased patient comfort and reduced adverse effects.

Recent Findings

Recent innovations and techniques are discussed including pharmacologic drugs targeting sodium and calcium channels, peptide-based pharmacologic drugs, and non-medicinal methods of alleviating pain such as soothing music or virtual reality.

Summary

The present investigation included review of current literature on the application of these innovative technologies, analyzing mechanisms of action, pharmacokinetics, and clinical effectiveness. Our study also investigated the potential benefits in terms of pain relief, reduced side effects, and improved patient adherence. The research critically examines the challenges and considerations associated with implementing these technologies in acute pain management, considering factors like cost, accessibility, and regulatory aspects. Additionally, case studies and clinical trials are highlighted which demonstrate practical implications of these novel medication technologies in real-world scenarios. The findings aim to provide healthcare professionals with a comprehensive understanding of the evolving landscape in acute pain management while guiding future research and clinical practices toward optimizing their use in enhancing patient care.

Norn S, Kruse PR, Kruse E. [History of opium poppy and morphine]. Dan Med Arbog. 2005;33:171–84.

Collier R. A short history of pain management. CMAJ Can Med Assoc J. 2018;190(1):E26–7. https://doi.org/10.1503/cmaj.109-5523.CrossRef

Nafziger AN, Barkin RL. Opioid therapy in Acute and Chronic Pain. J Clin Pharmacol. 2018;58(9):1111–22. https://doi.org/10.1002/jcph.1276.CrossRefPubMed

Robinson DH, Toledo AH. Historical development of modern anesthesia. J Investig Surg off J Acad Surg Res. 2012;25(3):141–9. https://doi.org/10.3109/08941939.2012.690328.CrossRef

• Strand N, Tieppo Francio JM. Advances in Pain Medicine: a review of New technologies. Curr Pain Headache Rep. 2022;26(8):605–16. https://doi.org/10.1007/s11916-022-01062-6. This resource provided valuable insight into recent developments of patient care aimed at increasing personalized care. The methods include nerve stimulation and neuromodulation. New technologies are the forefront for researching new ways of modulating pain treatment.CrossRefPubMedPubMedCentral

Holden R, Holden J. Music: a better alternative than pain? Br J Gen Pract. 2013;63(615):536. https://doi.org/10.3399/bjgp13X673748.CrossRefPubMedPubMedCentral

• Babaie S, Taghvimi A, Hong JH, Hamishehkar H, An S, Kim KH. Recent advances in pain management based on nanoparticle technologies. J Nanobiotechnol. 2022;20(1):290. https://doi.org/10.1186/s12951-022-01473-y. Application of nanoparticle technology is important for uncovering potentially beneficial treatments at the microscopic level, both in their modulation of specific pain pathways and anatomic mechanisms.CrossRef

Smith V, Warty RR, Sursas JA, et al. The effectiveness of virtual reality in managing Acute Pain and anxiety for medical inpatients: systematic review. J Med Internet Res. 2020;22(11):e17980. https://doi.org/10.2196/17980.CrossRefPubMedPubMedCentral

Kushnarev M, Pirvulescu IP, Candido KD, Knezevic NN. Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers. Expert Opin Investig Drugs. 2020;29(3):259–71. https://doi.org/10.1080/13543784.2020.1728254.CrossRefPubMed

10.

• Nguyen PT, Yarov-Yarovoy V. Towards Structure-Guided Development of Pain Therapeutics Targeting Voltage-Gated Sodium Channels. Front Pharmacol. 2022;13. Accessed 15 Jan 2024. https://www.frontiersin.org/articles/https://doi.org/10.3389/fphar.2022.842032. This source offered the most comprehensive view into the study of both targeted sodium channels and the medications designed to decrease pain transmission by its target.

11.

Cheng X, Choi JS, Waxman SG, Dib-Hajj SD. Mini-review - sodium channels and beyond in peripheral nerve disease: modulation by cytokines and their effector protein kinases. Neurosci Lett. 2021;741:135446. https://doi.org/10.1016/j.neulet.2020.135446.CrossRefPubMed

12.

Vetter I, Deuis JR, Mueller A, et al. NaV1.7 as a pain target – from gene to pharmacology. Pharmacol Ther. 2017;172:73–100. https://doi.org/10.1016/j.pharmthera.2016.11.015.CrossRefPubMed

13.

Alexandrou AJ, Brown AR, Chapman ML, et al. Subtype-selective small molecule inhibitors reveal a fundamental role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release. PLoS ONE. 2016;11(4):e0152405. https://doi.org/10.1371/journal.pone.0152405.CrossRefPubMedPubMedCentral

14.

Safina BS, McKerrall SJ, Sun S, et al. Discovery of Acyl-Sulfonamide Nav1.7 inhibitors GDC-0276 and GDC-0310. J Med Chem. 2021;64(6):2953–66. https://doi.org/10.1021/acs.jmedchem.1c00049.CrossRefPubMed

15.

Schmalhofer WA, Calhoun J, Burrows R, et al. ProTx-II, a selective inhibitor of NaV1.7 Sodium channels, blocks Action potential propagation in nociceptors. Mol Pharmacol. 2008;74(5):1476–84. https://doi.org/10.1124/mol.108.047670.CrossRefPubMed

16.

Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov. 2009;8(1):55–68. https://doi.org/10.1038/nrd2757.CrossRefPubMedPubMedCentral

17.

Tibbs GR, Posson DJ, Goldstein PA. Voltage-gated Ion channels in the PNS: Novel therapies for Neuropathic Pain? Trends Pharmacol Sci. 2016;37(7):522–42. https://doi.org/10.1016/j.tips.2016.05.002.CrossRefPubMed

18.

•• Allen D, Hanumantharao SN, McDonell R, et al. Preclinical characterization of the efficacy and safety of biologic N-001 as a novel pain analgesic for post-operative acute pain treatment. Sci Rep. 2023;13(1):11778. https://doi.org/10.1038/s41598-023-38618-4. Looking to real-world pathologies may have intrinsic benefit to understanding both the pathology itself and howsimilar mechanisms may in fact have beneficial outcomes in patients. It is of even greater importance to understandthese outcomes in comparison to known treatments of pain modulation.CrossRefPubMedPubMedCentral

19.

Tsuge H, Nagahama M, Oda M, et al. Structural basis of actin recognition and arginine ADP-ribosylation by Clostridium perfringens iota-toxin. Proc Natl Acad Sci U S A. 2008;105(21):7399–404. https://doi.org/10.1073/pnas.0801215105.CrossRefPubMedPubMedCentral

20.

• Nguyen PT, Nguyen HM, Wagner KM, et al. Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of pain. eLife. 2022;11:e81727. https://doi.org/10.7554/eLife.81727. In order to treat pain, one must first understand the mechanism by which pain is conferred, transmitted andunderstood within the human body. Biologic manifestations of pain may also reveal valuable pathways ofmodulating it.CrossRefPubMedPubMedCentral

21.

Hameed S. Nav1.7 and Nav1.8: role in the pathophysiology of pain. Mol Pain. 2019;15:1744806919858801. https://doi.org/10.1177/1744806919858801.CrossRefPubMedPubMedCentral

22.

Protein Engineering for Chronic Pain | NIH HEAL Initiative, Published. May 6, 2021. Accessed 16 Jan 2024. https://heal.nih.gov/news/stories/protein-engineering-chronic-pain.

23.

Jayakar S, Shim J, Jo S, Bean BP, Singeç I, Woolf CJ. Developing nociceptor-selective treatments for acute and chronic pain. Sci Transl Med. 2021;13(619):eabj9837. https://doi.org/10.1126/scitranslmed.abj9837.CrossRefPubMedPubMedCentral

24.

Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005;57(4):411–25. https://doi.org/10.1124/pr.57.4.5.CrossRefPubMed

25.

•• Cizkova D, Marsala J, Lukacova N, et al. Localization of N-type Ca2 + channels in the rat spinal cord following chronic constrictive nerve injury. Exp Brain Res. 2002;147(4):456–63. https://doi.org/10.1007/s00221-002-1217-3. Specific patterns of nerve injury and subsequent physiologic changes provide valuable targets to tailor specific treatment of pain. Understanding expression of ion channels in response to injury allows researchers to discover potentially new treatments.CrossRefPubMed

26.

Park JF, Luo ZD. Calcium channel functions in pain processing. Channels. 2010;4(6):510–7. https://doi.org/10.4161/chan.4.6.12869.CrossRefPubMedPubMedCentral

27.

Adams DJ, Berecki G. Mechanisms of conotoxin inhibition of N-type (ca(v)2.2) calcium channels. Biochim Biophys Acta. 2013;1828(7):1619–28. https://doi.org/10.1016/j.bbamem.2013.01.019.CrossRefPubMed

28.

Adams DJ, Callaghan B, Berecki G. Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (CaV2.2) calcium channels. Br J Pharmacol. 2012;166(2):486–500. https://doi.org/10.1111/j.1476-5381.2011.01781.x.CrossRefPubMedPubMedCentral

29.

• Choudhary S, Kaur R, Waziri A, Garg A, Kadian R, Alam MS. N-type calcium channel blockers: a new approach towards the treatment of chronic neuropathic pain. Explor Med. Published Online Febr. 2023;28:85–106. https://doi.org/10.37349/emed.2023.00126. This source offered us the most recent look into calcium channel modulators, as it was published less than a year ago.

30.

Doggrell SA. Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs. 2004;13(7):875–7. https://doi.org/10.1517/13543784.13.7.875.CrossRefPubMed

31.

• Wie CS, Derian A. Ziconotide. In: StatPearls. StatPearls Publishing; 2023. Accessed 19 Jan 2024. http://www.ncbi.nlm.nih.gov/books/NBK459151/. Ziconotide offers another example of using compounds found in nature to modulate pain responses in humans. Blockade of calcium channels but not opioid receptors offers a potential non-opioid alternative in modulating pain response.

32.

Nair AS, Poornachand A, Kodisharapu PK, Ziconotide. Indications, adverse effects, and limitations in Managing Refractory Chronic Pain. Indian J Palliat Care. 2018;24(1):118–9. https://doi.org/10.4103/IJPC.IJPC_113_17.CrossRefPubMedPubMedCentral

33.

Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008;105(9):3628–33. https://doi.org/10.1073/pnas.0708930105.CrossRefPubMedPubMedCentral

34.

• Yasaei R, Katta S, Saadabadi A. Gabapentin. In: StatPearls. StatPearls Publishing; 2023. Accessed 19 Jan 2024. http://www.ncbi.nlm.nih.gov/books/NBK493228/. FDA-approved medications warrant even further study as they may exhibit alternative uses beyond their original scope of treatment. Gabapentin is an example of a drug originally used for a specific use which was found to have further uses beyond its original scope.

35.

Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137–50. https://doi.org/10.1016/j.eplepsyres.2006.09.008.CrossRefPubMed

36.

Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014;12(1):44–56. https://doi.org/10.2174/1570159X1201140117162802.CrossRefPubMedPubMedCentral

37.

• Gomez K, Santiago U, Nelson TS, et al. A peptidomimetic modulator of the CaV2.2 N-type calcium channel for chronic pain. Proc Natl Acad Sci U S A. 2023;120(47). https://doi.org/10.1073/pnas.2305215120. Further study of channels which already have medications aimed at their augmentation is still warranted, as new channel modulators provide an opportunity for a similar decrease in pain transmission but also offer a different or perhaps lessened side effect profile.

38.

Lee S, Jo S, Talbot S, et al. Novel charged sodium and calcium channel inhibitor active against neurogenic inflammation. eLife. 2019;8:e48118. https://doi.org/10.7554/eLife.48118.CrossRefPubMedPubMedCentral

39.

• Antunes FTT, Campos MM, Carvalho V, de PR, et al. Current Drug Development Overview: Targeting Voltage-gated Calcium channels for the treatment of Pain. Int J Mol Sci. 2023;24(11):9223. https://doi.org/10.3390/ijms24119223. Variation in channels with similar ligands (i.e. Calcium channels (L-type, N-type, etc.)) offers potentially different manifestations via differential transmission and warrants further research.CrossRefPubMedPubMedCentral

40.

Miller K, Rodger S, Kipping B, Kimble RM. A novel technology approach to pain management in children with burns: a prospective randomized controlled trial. Burns J Int Soc Burn Inj. 2011;37(3):395–405. https://doi.org/10.1016/j.burns.2010.12.008.CrossRef

41.

Kia Z, Allahbakhshian M, Ilkhani M, Nasiri M, Allahbakhshian A. Nurses’ use of non-pharmacological pain management methods in intensive care units: a descriptive cross-sectional study. Complement Ther Med. 2021;58:102705. https://doi.org/10.1016/j.ctim.2021.102705.CrossRefPubMed

42.

• Shi Y, Wu W. Multimodal non-invasive non-pharmacological therapies for chronic pain: mechanisms and progress. BMC Med. 2023;21(1):372. https://doi.org/10.1186/s12916-023-03076-2. Modulation of pain signals may not prevent the painful stimulus from occurring, but it can prevent the body from experiencing the typical pain sensation, which would improve patient outcomes.CrossRefPubMedPubMedCentral

43.

• Grassini S. Virtual reality assisted non-pharmacological treatments in Chronic Pain Management: a systematic review and quantitative Meta-analysis. Int J Environ Res Public Health. 2022;19(7):4071. https://doi.org/10.3390/ijerph19074071. Virtual reality provides a most-promising option for non-pharmacologic treatment, virtual reality also offers a wider.CrossRefPubMedPubMedCentral

44.

Mota M, Cunha M, Santos MR, Silva D, Santos E, Choudhary S, Kaur R, Waziri A, Garg A, Kadian R, Alam MS. Non-pharmacological interventions for pain management in adult victims of trauma: a scoping review protocol. JBI Database Syst Rev Implement Rep. 2019;17(12):2483–90 10.11124/JBISRIR-2017-004036.CrossRef

Titel: Emerging Medications and Strategies in Acute Pain Management: Evolving Role of Novel Sodium and Calcium Channel Blockers, Peptide-Based Pharmacologic Drugs, and Non-Medicinal Methods
verfasst von: Alan D. Kaye
Driskell R. Greene
Catherine Nguyen
Amanda Ragland
Mason P. Granger
William Peyton Wilhite
Kylie Dufrene
Sahar Shekoohi
Christopher L. Robinson
Publikationsdatum: 18.05.2024
Verlag: Springer US
Erschienen in: Current Pain and Headache Reports
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-024-01265-z

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Schlaganfall: frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Emerging Medications and Strategies in Acute Pain Management: Evolving Role of Novel Sodium and Calcium Channel Blockers, Peptide-Based Pharmacologic Drugs, and Non-Medicinal Methods

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Schlaganfall: frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

Reanimation bei Kindern – besser vor Ort oder während Transport?

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Update AINS

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Schlaganfall: frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

Reanimation bei Kindern – besser vor Ort oder während Transport?

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Update AINS